Idiopathic erythema multiforme: Evidence of underlying Janus kinase–signal transducer and activator of transcription activation and successful treatment with tofacitinib

JAAD Case Reports

Volumn 2, Issue 6, 2016, Pages 502-504

  Damsky, William ^a   King, Brett A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chronic erythema multiforme; erythema multiforme; Janus kinase signal transducer and activator of transcription; recurrent erythema multiforme; tofacitinib; tricho rhino phalangeal syndrome

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; JANUS KINASE; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISONE; TOFACITINIB; VALACICLOVIR;

ADULT; ARTICLE; CANCER STAGING; CASE REPORT; CYTOMEGALOVIRUS; DERMOEPIDERMAL JUNCTION; DISEASE DURATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; EPSTEIN BARR VIRUS; ERYTHEMA MULTIFORME; FEMALE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IMMUNOFLUORESCENCE; KERATINOCYTE; MEDICAL HISTORY; NONHUMAN; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN BIOPSY; TRANSCRIPTION INITIATION;

EID: 85002862269     PISSN: None     EISSN: 23525126     Source Type: Journal    
DOI: 10.1016/j.jdcr.2016.10.009     Document Type: Article

References (10)

1. 1 Wetter, D.A., Davis, M.D., Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007. J Am Acad Dermatol 62 (2010), 45–53.
2. 2 Maas, S.M., Shaw, A.C., Bikker, H., et al. Phenotype and genotype in 103 patients with tricho-rhino-phalangeal syndrome. Eur J Med Genet 58 (2015), 279–292.
3. 3 Fujisawa, T., Fukao, T., Shimomura, Y., Seishima, M., A novel TRPS1 mutation in a family with tricho-rhino-phalangeal syndrome type 1. J Dermatol 41 (2014), 514–517.
4. 4 Ito, T., Shimomura, Y., Farooq, M., Suzuki, N., Sakabe, J., Tokura, Y., Trichorhinophalangeal syndrome with low expression of TRPS1 on epidermal and hair follicle epithelial cells. J Dermatol 40 (2013), 396–398.
5. 5 Suemoto, H., Muragaki, Y., Nishioka, K., et al. Trps1 regulates proliferation and apoptosis of chondrocytes through Stat3 signaling. Dev Biol 312 (2007), 572–581.
6. 6 Caproni, M., Torchia, D., Schincaglia, E., et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 155 (2006), 722–728.
7. 7 Higgins, E., Al Shehri, T., McAleer, M.A., et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 135 (2015), 551–553.
8. 8 Craiglow, B.G., King, B.A., Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 134 (2014), 2988–2990.
9. 9 Craiglow, B.G., King, B.A., Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatol 151 (2015), 1110–1112.
10. 10 Hornung, T., Janzen, V., Heidgen, F.J., Wolf, D., Bieber, T., Wenzel, J., Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med 371 (2014), 2537–2538.